ArticleAmerican journal of translational research2021
Clinical efficacy of jade wind-barrier powder combined with loratadine in the treatment of pediatric allergic rhinitis.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of combined loratadine and mometasone furoate therapy in allergic rhinitis patients.Frontiers in immunology · 2025Trial
- Traditional Chinese Medicine for Pediatric Allergic Diseases.Current allergy and asthma reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical efficacy of Jade Wind-Barrier Powder combined with Loratadine in the treatment of pediatric allergic rhinitis (PAR).
methodsThe clinical data of 101 children with allergic rhinitis (AR) admitted to the Affiliated Hospital of Qingdao University and Affiliated Hospital of Nanjing University of Traditional Chinese Medicine from January 2019 to December 2019 were retrospectively analyzed. The children were randomly divided into Group A (n=50) and Group B (n=51) in accordance with a random number table. Group A was treated with Loratadine only, while Group B was treated with Loratadine combined with Jade Wind-Barrier powder. The clinical efficacy, symptom disappearance time, symptom scores before and after treatment, indices of immunological function, changes in the indices of inflammatory factors and disease recurrence were compared between the two groups.
resultsThe overall response rate (ORR) in Group B (96.08%) was higher than that in Group A (76.00%) (
conclusionJade Wind-Barrier powder combined with Loratadine can improve clinical symptoms, immunity, inflammation levels and disease recurrence rate of PAR patients, with a significant clinical efficacy.
Indexed as
Identifiers
34306392PMC8290791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.